Skip to content

QuartzBio, a A part of Precision for Drugs, Acquires SolveBio and Expands Software program-as-a-Service (SaaS) Knowledge Administration Options for Scientific Analysis & Growth (R&D)

QuartzBio’s suite of end-to-end SaaS options supplies pharmaceutical and biotech purchasers with a totally related information ecosystem linking pattern, biomarker, and scientific information to enhance collaboration, planning and R&D productiveness.

FREDERICK, Md., Jan 24, 2023 /PRNewswire/ — Precision for Drugs, the primary international, precision drugs scientific analysis providers group, as we speak introduced the strategic acquisition of SolveBio by QuartzBio.

SolveBio’s clever applied sciences and enterprise information administration platform has built-in into QuartzBio’s suite of SaaS options, offering a single, scalable answer supporting scientific pattern stock administration and biomarker information administration for the biotech and pharmaceutical sectors.

The mixed choices below QuartzBio present scientific and operations groups in drug growth with an agile, user-friendly information administration platform that allows enterprise-level visibility throughout the lifecycle of their pattern and biomarker information. Leveraging this expanded enterprise suite of options, scientists in translational analysis and scientific operations can extra simply collaborate throughout features, analyze and report on key datasets, and generate insights.

“We’re excited to have SolveBio becoming a member of forces with QuartzBio,” says Scott Marshall, Ph.D., Common Supervisor of QuartzBio. “As our business continues to innovate, it’s crucial that we proceed to advance our portfolio of enterprise options to allow scale and connectivity in help of our final objective – delivering therapies to sufferers. Integrating SolveBio’s know-how with QuartzBio’s present portfolio helps us accomplish that. “

QuartzBio’s absolutely related, end-to-end SaaS options are engineered to allow seamless monitoring and monitoring of scientific pattern standing, knowledgeable consent kind (ICF) monitoring/coding, and administration of biomarker information throughout the enterprise, leading to a unified answer for the administration and supply of each samples and their associated biomarker information. The platform is used to generate scientific and operational insights, whereas research are in progress, after research are full, and throughout a number of scientific packages.

Combining the QuartzBio and SolveBio groups’ experience and scale, QuartzBio can now higher help purchasers’ strategic objectives and day-to-day productiveness by serving to scientific and translational groups:

  • Save time with know-how that maps information as-is, from any supply, utilizing the format offered by the lab, vendor, or different supply techniques with no adjustments required—growing flexibility and dashing deployment.
  • Acquire visibility into pattern standing with digital Pattern Stock Administration, a single supply of fact linking samples and derivatives with scientific information, knowledgeable consent, transport standing, and extra – throughout a number of websites, labs, and repositories.
  • Enhance effectivity and reporting accuracy with enterprise-wide Biomarker Knowledge Administrationas all sample-related information can be centralized and harmonized in a unified information platform, thus eliminating the necessity to seek for information in a number of storage areas.
  • Consolidate visibility to saved samples from all research (lively and inactive) with digital Biorepository, throughout geographies, biorepositories, and central labs (long-term storage) to facilitate planning for future information technology.
  • Collaborate and join by leveraging biomarker-specific visualizations (eg, genomic and circulation information modules), shareable dashboards, inside and exterior notifications, and utility programming interfaces (APIs)/connectors that permit the QuartzBio options to empower determination making within the context of a fancy information ecosystem .

“We’re very excited to hitch Precision for Drugs and develop into part of QuartzBio,” says Mark Kaganovich, SolveBio’s Founder and CEO. “It is a huge alternative to proceed enhancing our providing to our clients.” “QuartzBio’s acquisition of SolveBio is a significant step ahead in our objective to resolve biomarker information administration for the pharmaceutical and biotech business,” says david caplan, SolveBio’s Co-Founder and CTO. “By becoming a member of QuartzBio’s wonderful workforce, we will present the great answer our purchasers must get precision remedies out to sufferers quicker. We’re honored to be part of this journey.”

About Precision for Drugs

Precision for Drugs is the primary biomarker-driven scientific analysis providers group supporting life sciences corporations in the usage of biomarkers important to concentrating on affected person remedies extra exactly and successfully. Precision applies novel biomarker approaches to scientific analysis that combine scientific trial design and execution with deep scientific information, laboratory experience and superior information sciences. This convergence of trials, labs and information sciences is driving quicker scientific growth and approval. Precision for Drugs is a part of the Precision Drugs Group, with 3,200 folks in 40 areas within the US, Canada, Europe and Australia. For extra data, go to

About QuartzBio

QuartzBio helps overcome the information chaos inherent in fashionable drug growth. We serve scientific operations and translational analysis groups in oncology, autoimmune, CNS and different biomarker-rich therapeutic areas, whose progress hinges on navigating and connecting a fancy information ecosystem. Our suite of absolutely related, end-to-end SaaS options is particularly engineered to handle the challenges of each pattern information and biomarker information administration – ​​offering a single, scalable information platform answer to the biotech and pharma sectors. For extra data, go to

About SolveBio

SolveBio is an business chief in superior precision drugs information analytics. Its know-how platform permits biopharma clients to decrease trial danger, create more practical therapeutics, and compress the time scale of scientific growth. The core of SolveBio’s platform is know-how to attach genomic information that comes from a quickly compounding complicated panorama of distributors, research, and sufferers.

Media Contact:
Ann SmithPrecision Drugs Group Media Relations
[email protected]

SOURCE Precision for Drugs, Inc.


Leave a Reply

Your email address will not be published. Required fields are marked *